Ketamine/Esketamine for Treatment-Resistant Anxiety Disorders
A patient who has failed five adequate GAD trials asks about ketamine after reading about its use for depression. The debate turns on a label that doesn't cover her at all, and evidence that, while real, isn't nearly as deep as what she read about.
Nadia F., a 38-year-old woman, has generalized anxiety disorder that has not responded adequately to five separate adequate trials over six years — sertraline, venlafaxine, escitalopram, buspirone augmentation, and a supervised course of cognitive-behavioral therapy — each with partial benefit followed by plateau or intolerable side effects. She works part-time as a graphic designer, has scaled back her hours twice due to her symptoms, and is asking specifically about ketamine after reading about its use for depression and wondering whether it could help her anxiety as well.
Esketamine carries FDA approval only for treatment-resistant depression and depression with suicidal ideation, not for anxiety disorders in isolation; her presentation has no depressive component to anchor an on-label esketamine indication. Off-label ketamine use for treatment-resistant anxiety is an active, emerging area, with some open-label and small controlled trials suggesting real benefit, particularly for comorbid or anxiety-predominant presentations, but the evidence base remains substantially thinner than for depression, dosing protocols aren't standardized the way esketamine's are, and there is no counterpart to the REMS program that governs where esketamine may be given and how long patients must be observed afterward, and monitoring requirements for dissociation and blood-pressure effects still apply regardless of which indication is being treated.
She's candid that a friend with treatment-resistant depression had a genuinely transformative response to esketamine, which is the specific reason she's asking now rather than at any point during her six years of prior treatment — worth naming explicitly, since her expectations are being shaped by a different diagnosis with a considerably stronger evidence base than her own.
The clinician is careful not to dismiss the comparison outright — the underlying glutamatergic mechanism ketamine and esketamine share is real and mechanistically distinct from anything she's tried so far, which is itself part of the honest rationale for offering it despite the label mismatch, not a reason to wave the request away.
An emerging option after five failed trials
Esketamine's actual FDA approval doesn't cover her presentation at all — it's indicated for treatment-resistant depression and depression with suicidal ideation, and she has no depressive component to anchor either indication. Any ketamine use here would be genuinely off-label, not just an off-label dose or route within an approved indication.
The off-label evidence for anxiety specifically, while real and growing, is meaningfully thinner than the depression literature that supported esketamine's actual approval — smaller trials, less standardized dosing, less long-term safety data in this specific population. That's worth being explicit with her about, distinct from simply saying "it's off-label," since the depth of evidence, not just the label status, is what should shape how strongly this gets recommended.
Given five genuinely adequate prior trials and real functional impact, I think this is a defensible next step to offer — but it should be framed to her honestly as an emerging, off-label option with a thinner evidence base than what she read about for depression, administered with the same dissociation and blood-pressure monitoring ketamine requires regardless of indication, not as an established anxiety treatment.
Agreed: she'll proceed with off-label IV ketamine under standard dissociation/blood-pressure monitoring protocols, with the off-label status and thinner anxiety-specific evidence base explicitly documented in the informed consent discussion.